Tt for cerebral malaria pharmacology
Reading File
Finding Sources
Finding Sources
Searching PubMed
"cerebral malaria" AND treatment
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Searching Images
cerebral malaria treatment artesunate mechanism
I now have all the content needed for a thorough answer. Here is the complete pharmacology-focused treatment guide for cerebral malaria:
Treatment of Cerebral Malaria - Pharmacology
Background
Cerebral malaria complicates approximately 2% of cases of Plasmodium falciparum malaria - it carries a 20-30% mortality if untreated. It is defined as impaired consciousness/coma or repeated seizures in the setting of falciparum malaria with no other explanation. The condition involves cytoadherence of parasitized erythrocytes to cerebral capillaries and venules, leading to sequestration, small necrotic foci (Dürck nodes), and diffuse cerebral edema.
First-Line Drug: IV Artesunate
Artesunate is the WHO-endorsed drug of choice for severe/cerebral malaria. It is superior to quinine in both adults and children.
| Feature | Detail |
|---|---|
| Drug class | Artemisinin derivative (sesquiterpene lactone endoperoxide) |
| Mechanism | Activated by intraparasitic heme iron → free radicals that alkylate parasite proteins; kills all erythrocytic stages including early rings (unlike quinine) |
| Dosing (IV/IM) | 2.4 mg/kg on admission, then at 12 h, 24 h, then once daily |
| Advantages | Faster parasite clearance (within 12 h vs 24-48 h for quinine), lower mortality, no cardiac toxicity, no hypoglycemia |
| Parasite clearance | Asexual parasites should be undetectable within 5 days |
| Duration | Minimum 24 h parenterally; switch to oral ACT once patient tolerates oral drugs |
Indications for IV treatment: impaired consciousness, seizures, severe systemic manifestations (hyperpyrexia >40°C, hypotension, jaundice, ARDS, bleeding).
- Adams and Victor's Principles of Neurology, 12th Ed.
- Tintinalli's Emergency Medicine
Alternative: IV Quinine (when artesunate unavailable)
| Feature | Detail |
|---|---|
| Drug class | Cinchona alkaloid |
| Mechanism | Intercalates with parasite DNA, interferes with heme polymerization (forms toxic free heme) |
| Dosing | Loading dose: 20 mg quinine salt/kg IV (infusion or divided IM), then 10 mg/kg 8-hourly; infusion rate must not exceed 5 mg/kg/hour |
| Loading dose caveat | Do NOT give loading dose if patient already received quinine |
| Completion | Oral quinine 10 mg/kg TDS + doxycycline 100 mg OD (OR clindamycin in pregnancy/children <8 yrs) to complete 7 days total |
| Adverse effects | Hypoglycemia (potent insulin secretagogue - especially dangerous in pregnancy), cardiac toxicity (QTc prolongation, myocardial depression) - requires continuous cardiac monitoring |
| Resistance | Partial resistance reported in Southeast Asia |
- Park's Textbook of Preventive and Social Medicine
- Tintinalli's Emergency Medicine
Other Artemisinin Derivatives (parenteral options)
| Drug | Dosing | Notes |
|---|---|---|
| Artemether (IM) | 3.2 mg/kg loading, then 1.6 mg/kg/day | Less preferred than IV artesunate for cerebral malaria due to erratic IM absorption in shocked patients |
| Arteether (IM) | 150 mg/day for 3 days | Adults only; NOT recommended in children |
Step-Down / Follow-up Oral Treatment (after ≥24-48 h of parenteral therapy)
Once the patient can take oral medications, complete treatment with area-specific ACT (Artemisinin Combination Therapy):
- North-East India / high-resistance zones: ACT-AL (artemether-lumefantrine) × 3 days + primaquine single dose (day 2)
- Other regions: ACT-SP (artesunate-sulfadoxine-pyrimethamine) × 3 days + primaquine single dose
Avoid mefloquine in cerebral malaria - associated with neuropsychiatric complications.
Adjunctive / Supportive Pharmacology
| Intervention | Evidence | Comment |
|---|---|---|
| Anticonvulsants | Indicated | For seizures; benzodiazepines acutely |
| Dexamethasone/corticosteroids | NOT recommended | Most trials show no benefit; may worsen outcomes; do not use |
| Heparin | Harmful/unproven | Do not use |
| Pentoxifylline | Unproven | Do not use |
| Iron chelators | Unproven | Do not use |
| Dichloroacetate | Unproven | Do not use |
| Exchange transfusion | Modest possible benefit | May be considered in very high parasitemia with severe disease |
| Hypoglycemia correction | Mandatory | Especially when using quinine/quinidine (which stimulate insulin release) |
Key point from Tintinalli's: "Glucocorticoids are of no proven benefit for cerebral malaria and should not be used."
Special Populations
Pregnancy:
- Artemisinins are probably safe but restricted in the 1st trimester
- Quinine can be used but carries higher hypoglycemia risk due to hypertrophied pancreatic β-cells; monitor blood glucose closely
- Use clindamycin (not doxycycline) to complete 7 days
Children:
- Most susceptible in hyperendemic regions
- IV artesunate is superior in children too
- Arteether is NOT recommended in children
- Risk of neurologic sequelae (especially if seizures during treatment or ischemic injury on MRI)
Drug Comparison Summary
| Parameter | Artesunate (IV) | Quinine (IV) |
|---|---|---|
| Parasite clearance speed | Faster (~12 h) | Slower (24-48 h) |
| Mortality | Lower | Higher |
| Cardiac toxicity | None | Yes (QTc prolongation) |
| Hypoglycemia | No | Yes (especially in pregnancy) |
| Stages killed | All erythrocytic stages | Mainly late trophozoites/schizonts |
| Current WHO preference | 1st line | 2nd line (if artesunate unavailable) |
Sources
- Adams and Victor's Principles of Neurology, 12th Ed. - Malaria section
- Tintinalli's Emergency Medicine - Complications of treatment, severe malaria
- Harrison's Principles of Internal Medicine 22E (2025) - Cerebral malaria
- Park's Textbook of Preventive and Social Medicine - Treatment of severe malaria
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Malaria (neuropsychiatric aspects)
Means if person w.t 60 kg then 600 mg quinine
Yes, exactly right.
Quinine Dosing for a 60 kg Patient
Loading Dose
20 mg/kg × 60 kg = 1200 mg quinine salt IV (not 600 mg)
Maintenance Dose
10 mg/kg × 60 kg = 600 mg quinine salt IV, every 8 hours
So the 600 mg figure applies to the maintenance dose, not the loading dose.
| Dose | Calculation | Amount |
|---|---|---|
| Loading (admission) | 20 mg/kg × 60 kg | 1200 mg |
| Maintenance (8-hourly) | 10 mg/kg × 60 kg | 600 mg |
Key Rules to Remember
- Infusion rate must not exceed 5 mg/kg/hour (= max 300 mg/hour for this patient) - faster infusion risks fatal arrhythmia
- Do not give the loading dose if the patient already received quinine before referral
- Monitor ECG continuously (QTc prolongation risk)
- Check blood glucose frequently (quinine stimulates insulin release → hypoglycemia)
Are there any questions asked in fmge or neetpg of this topic
Searching the Web
FMGE NEET PG cerebral malaria treatment questions asked previous years
Searching the Web
NEET PG FMGE MCQ artesunate quinine cerebral malaria pharmacology previous year
Yes, this is a high-yield topic for both FMGE and NEET PG. Here are the commonly asked questions and patterns:
Previously Asked / High-Yield MCQs on Cerebral Malaria
1. Drug of Choice - Most Frequently Asked
Q. Drug of choice for severe/cerebral malaria is?
- A) Quinine IV
- B) Chloroquine
- C) IV Artesunate ✓
- D) Mefloquine
This is the single most repeated concept. Answer is always IV Artesunate.
2. FMGE Dec 2021 (Directly Asked)
Q. A patient from a North-Eastern state diagnosed with P. falciparum malaria. Most appropriate treatment?
- A) Artemether + Lumefantrine ✓
- B) Sulfadoxine + Pyrimethamine
- C) Chloroquine
- D) Mefloquine
North-East India is a chloroquine-resistant zone - ACT-AL is the answer.
3. Adjunctive Therapy - Commonly Asked
Q. Which of the following is NOT recommended in cerebral malaria?
- A) Anticonvulsants
- B) IV Fluids
- C) Dexamethasone/Corticosteroids ✓ (NOT recommended)
- D) Artesunate
4. Quinine Adverse Effects
Q. Which complication is most feared with IV quinine in cerebral malaria in pregnancy?
- A) Nephrotoxicity
- B) Hypoglycemia ✓ (potent insulin secretagogue)
- C) Hepatotoxicity
- D) Pulmonary edema
5. Mefloquine
Q. Which drug should be AVOIDED in cerebral malaria?
- A) Artesunate
- B) Artemether
- C) Mefloquine ✓ (neuropsychiatric complications)
- D) Quinine
6. Parasite Clearance Speed
Q. Compared to quinine, artesunate clears parasites:
- A) More slowly
- B) At the same rate
- C) Faster (kills all erythrocytic stages including early rings) ✓
- D) Only kills gametocytes
High-Yield Points to Lock In
| Point | Exam Answer |
|---|---|
| DOC for severe/cerebral malaria | IV Artesunate |
| DOC when artesunate unavailable | IV Quinine |
| Drug to AVOID in cerebral malaria | Mefloquine (neuropsychiatric SE) |
| Corticosteroids in cerebral malaria | Contraindicated / No benefit |
| Quinine danger in pregnancy | Hypoglycemia |
| Quinine monitoring requirement | Cardiac (ECG) monitoring |
| Artesunate advantage | No cardiac toxicity, no hypoglycemia |
| NE India P. falciparum treatment | ACT-AL (artemether + lumefantrine) |
| Other states P. falciparum | ACT-SP (artesunate + SP) |
| Quinine infusion rate limit | Max 5 mg/kg/hour |
Bottom line: This topic comes under Pharmacology, PSM (Preventive Medicine), and Medicine in both FMGE and NEET PG. The DOC question (IV artesunate), the corticosteroids-are-contraindicated point, and mefloquine avoidance are the three most reliably tested facts.
Tt for chloroquine resistant falciparum malaria
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Excellent - now I have all the information needed for a comprehensive answer.
Treatment of Chloroquine-Resistant P. falciparum Malaria
Why Chloroquine Fails
Chloroquine-resistant P. falciparum is now the rule, not the exception in most endemic regions. Resistance is due to mutations in the pfcrt gene (chloroquine resistance transporter), which pumps the drug out of the parasite's food vacuole. Geographic areas where chloroquine still works are very limited (Central America west of Panama Canal, Haiti, Dominican Republic, Egypt, parts of the Middle East).
UNCOMPLICATED Chloroquine-Resistant P. falciparum
First-Line: Artemisinin-Based Combination Therapy (ACT)
ACT is the WHO-recommended treatment for chloroquine-resistant falciparum malaria worldwide. The artemisinin component acts rapidly; the partner drug acts longer to clear residual parasites and prevent resistance.
| ACT Regimen | Dose (Adult) | Duration | Notes |
|---|---|---|---|
| Artemether + Lumefantrine (Coartem) | 4 tabs (each 20/120 mg) twice daily | 3 days | Only ACT approved in USA; take with food/fat |
| Artesunate + Amodiaquine | 2 tabs once daily | 3 days | Not available in USA; widely used in Africa |
| Artesunate + Mefloquine | Artesunate 4 mg/kg/day + mefloquine | 3 days | Preferred in Southeast Asia |
| Dihydroartemisinin + Piperaquine | Weight-based, once daily | 3 days | High efficacy; concern in SE Asia now |
| Artesunate + SP (ACT-SP) | Artesunate 3 days + SP single dose | 3 days | Used in India (non-NE states) |
India-specific (National Programme):
- North-East states (high CQ & SP resistance): ACT-AL (artemether-lumefantrine) × 3 days + primaquine day 2
- Other states: ACT-SP (artesunate + sulfadoxine-pyrimethamine) × 3 days + primaquine day 2
Alternative (Non-ACT) Options
| Drug | Dose | Duration | Notes |
|---|---|---|---|
| Atovaquone-Proguanil (Malarone) | 4 adult tabs once daily | 3 days | Do NOT use if taken as prophylaxis (failure risk) |
| Quinine sulfate + Doxycycline | Quinine 650 mg 8-hourly + Doxy 100 mg BD | 3-7 days | Older regimen; quinine causes cinchonism |
| Quinine + Clindamycin | Quinine 650 mg 8-hourly + Clindamycin 600 mg BD | 7 days | Used in pregnancy (doxy contraindicated) |
| Mefloquine | 750 mg then 500 mg after 6-8 h (or 15 mg/kg once) | Single/split | Avoid in cerebral malaria (neuropsychiatric SE) |
SEVERE / Complicated Chloroquine-Resistant P. falciparum
This is the same as cerebral malaria treatment (discussed previously):
| Setting | Drug | Dose |
|---|---|---|
| 1st line | IV Artesunate | 2.4 mg/kg at 0h, 12h, 24h, then daily |
| If artesunate unavailable | IV Quinine | 20 mg/kg loading, then 10 mg/kg 8-hourly |
| Alternative parenteral | IM Artemether | 3.2 mg/kg loading, 1.6 mg/kg/day |
After ≥24-48h parenteral → switch to full oral ACT course.
Artemisinin Resistance - Emerging Threat
- Resistance to artemisinins has emerged in Southeast Asia (kelch13 gene mutations) - manifests as delayed parasite clearance (not treatment failure per se)
- Resistance to dihydroartemisinin-piperaquine is high in parts of SE Asia due to dual resistance
- Now emerging in Africa (Rwanda, Uganda) - major global concern
- For SE Asia border areas (especially Thai-Cambodia border): doxycycline is preferred for prophylaxis
Partner Drug Pharmacology
| Drug | Class | Mechanism | Key SE |
|---|---|---|---|
| Lumefantrine | Aryl amino alcohol | Heme polymerization inhibitor | QTc prolongation (mild) |
| Amodiaquine | 4-aminoquinoline | Like chloroquine | Agranulocytosis (long-term use) |
| Mefloquine | Quinoline methanol | Heme polymerization inhibitor | Neuropsychiatric effects, avoid in cerebral malaria |
| Piperaquine | Bisquinoline | Heme polymerization inhibitor | QTc prolongation |
| Atovaquone | Hydroxynaphthoquinone | Inhibits mitochondrial electron transport (Cyt bc1) | Resistance if used alone |
| Proguanil | Biguanide | DHFR inhibitor (antifolate) | Mouth ulcers |
| Sulfadoxine-Pyrimethamine (Fansidar) | Antifolate combo | DHPS + DHFR inhibition | Widespread resistance now; no longer recommended as monotherapy |
Quick Summary: Which ACT Where?
| Region | Recommended ACT |
|---|---|
| India - NE states | ACT-AL (artemether-lumefantrine) |
| India - other states | ACT-SP |
| Africa | Artemether-lumefantrine OR artesunate-amodiaquine |
| Southeast Asia | Artesunate-mefloquine (but resistance rising) |
| USA (imported cases) | Coartem (artemether-lumefantrine) or Malarone |
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, Katzung Basic & Clinical Pharmacology 16th Ed., Goldman-Cecil Medicine, Tintinalli's Emergency Medicine, Park's PSM
Chemoprophylaxis for malaria administration?
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Excellent - I now have all the data needed. Here's the complete chemoprophylaxis guide:
Malaria Chemoprophylaxis - Complete Guide
Core Principle
No prophylactic regimen is 100% protective. Non-pharmacological measures are equally important: DEET-based repellents (≥30%), permethrin-treated bed nets, avoiding mosquito exposure at dusk and dawn.
Drug-by-Drug Administration Guide
1. Chloroquine Phosphate
- Use: Only for chloroquine-sensitive areas (Central America west of Panama Canal, Haiti, Dominican Republic, Egypt, parts of Middle East)
- Dose: 300 mg base (500 mg salt) orally, once weekly, same day each week
- Start: 1-2 weeks before travel
- Stop: 4 weeks after leaving endemic area
- Pediatric: 5 mg/kg base weekly (max = adult dose)
- Cautions: May exacerbate psoriasis; retinal toxicity with >5 years use (6-monthly eye checks needed); narrow safety margin
2. Mefloquine (Lariam)
- Use: All areas with chloroquine-resistant malaria (except multidrug-resistant zones like Thai-Cambodia border)
- Dose: 250 mg (1 tablet) orally, once weekly, same day each week
- Start: 2-3 weeks before travel (to achieve therapeutic levels AND detect side effects before departure so an alternative can be arranged)
- Stop: 4 weeks after leaving endemic area
- Cautions: Contraindicated in history of convulsions, neuropsychiatric illness, cardiac conduction abnormalities; safe for long-term use if tolerated; best-documented drug for long-term travellers
3. Atovaquone-Proguanil (Malarone)
- Use: All areas including multidrug-resistant zones; drug of choice for short trips
- Dose: 1 adult tablet (250 mg atovaquone / 100 mg proguanil) orally, daily
- Start: 1-2 days before travel (shortest lead time - major advantage)
- Stop: 7 days after leaving endemic area (shortest post-travel duration - another advantage)
- Take with: Food or a milky drink (improves absorption)
- Pediatric dose:
| Weight | Dose |
|---|---|
| 5-8 kg | ¾ pediatric tab/day |
| >8-10 kg | ¾ pediatric tab/day |
| >10-20 kg | 1 pediatric tab/day |
| >20-30 kg | 2 pediatric tabs/day |
| >30-40 kg | 3 pediatric tabs/day |
| >40 kg | 1 adult tab/day |
- Cautions: Contraindicated if CrCl <30 mL/min (renal failure); NOT for pregnant women or infants <5 kg; do not use for treatment if already used as prophylaxis (risk of failure)
4. Doxycycline
- Use: All areas, especially multidrug-resistant zones (Thai-Myanmar border, Thai-Cambodia border) where mefloquine resistance is common
- Dose: 100 mg orally, daily
- Start: 1-2 days before travel
- Stop: 4 weeks after leaving endemic area
- Pediatric: ≥8 years only: 2 mg/kg/day up to 100 mg
- Cautions: Contraindicated in children <8 years and pregnant women; photosensitivity (use sunscreen); take with food/water (oesophageal ulceration risk); candidal vaginitis
5. Primaquine
- Use: Terminal prophylaxis to eradicate hypnozoites (liver dormant forms) of P. vivax and P. ovale; also causal prophylaxis in P. vivax-endemic areas
- Dose: 52.6 mg (30 mg base) daily for 14 days after travel (terminal prophylaxis)
- For primary prevention: 52.6 mg (30 mg base) daily throughout travel
- Mandatory prerequisite: Test for G6PD deficiency before use - causes severe haemolysis in G6PD-deficient patients
- Contraindicated: Pregnancy
6. Tafenoquine (newer)
- Use: Terminal prophylaxis of P. vivax and P. ovale; also primary prevention
- Dose: 200 mg once daily × 3 days pre-travel, then weekly; 1 week after last exposure
- G6PD testing mandatory before use
- Advantage over primaquine: single post-travel dose vs 14-day course
Summary Table - The Critical "START / STOP" Mnemonics
| Drug | Frequency | Start Before Travel | Stop After Travel | Area |
|---|---|---|---|---|
| Chloroquine | Weekly | 1-2 weeks | 4 weeks | CQ-sensitive only |
| Mefloquine | Weekly | 2-3 weeks | 4 weeks | CQ-resistant areas |
| Doxycycline | Daily | 1-2 days | 4 weeks | All areas incl. MDR |
| Atovaquone-Proguanil | Daily | 1-2 days | 7 days only | All areas incl. MDR |
| Primaquine | Daily | 1-2 days | 14 days (or 7 days) | P. vivax/ovale |
General Rules (Park's PSM)
- Prophylactic drugs must be taken with unfailing regularity throughout stay in endemic area
- Must be continued for 4 weeks after last possible exposure - parasites may still emerge from the liver during this period
- Long-term use (>6 weeks): monitor for chloroquine retinal changes (if on CQ for >3-5 years)
- Pregnant women: options are very limited - chloroquine (CQ-sensitive areas) or mefloquine (2nd/3rd trimester, CQ-resistant areas); avoid doxycycline, atovaquone-proguanil, primaquine, tafenoquine
Exam High-Yield Points
| Point | Answer |
|---|---|
| Prophylaxis with shortest pre-travel start | Doxycycline / Atovaquone-proguanil (1-2 days) |
| Prophylaxis with shortest post-travel duration | Atovaquone-proguanil (7 days only) |
| Why mefloquine starts 2-3 weeks early | To detect side effects AND achieve adequate blood levels |
| Prophylaxis for MDR zones (Thai border) | Doxycycline |
| Contraindicated in children <8 yrs | Doxycycline |
| G6PD testing required before | Primaquine, Tafenoquine |
| Safe in pregnancy (CQ-resistant area) | Mefloquine (2nd/3rd trimester) |
| Drug requiring renal function check | Atovaquone-proguanil (avoid if CrCl <30) |
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, Katzung Basic & Clinical Pharmacology 16th Ed., Park's Textbook of Preventive and Social Medicine, Goldman-Cecil Medicine
If person lives in endemic area for 1 year so he would take drug for a year and after 4 week leaving
Yes, that's exactly correct in principle. Let me clarify the full picture:
Long-Stay in Endemic Area (e.g., 1 Year)
The Rule
Drug is taken throughout the entire stay + 4 weeks after leaving (to cover any parasites that may still emerge from the liver after departure).
So for a 1-year stay:
- Take drug for ~52-53 weeks (the full year)
- Continue for 4 more weeks after leaving
- Total duration = ~13 months
But - Long-Term Prophylaxis Has Drug-Specific Limits
This is where it gets exam-relevant. Not all drugs are safe for 1 full year:
| Drug | Long-Term Safety | Specific Concern |
|---|---|---|
| Chloroquine | Generally safe | Retinal toxicity if >300 mg/week for >5 years → 6-monthly eye checks after 3-5 years |
| Mefloquine | Safe long-term if tolerated initially | Does not accumulate; no increased toxicity with long-term use |
| Doxycycline | Limited data on long-term use | GI side effects, candidiasis, photosensitivity over months |
| Atovaquone-Proguanil (Malarone) | Studied only up to 20 weeks formally; likely acceptable for longer based on individual component data | Not ideal for 1-year stays |
| Primaquine | Short courses only (14 days terminal) | Not recommended for 1-year prophylaxis |
Practical Recommendation for 1-Year Stay
| Area | Drug of Choice for Long Stay |
|---|---|
| CQ-sensitive area | Chloroquine weekly (safe for years) |
| CQ-resistant area | Mefloquine weekly (best-documented for long-term travelers) |
| MDR area (Thai border) | Doxycycline daily (limited long-term data but commonly used) |
Key Point for Exams
"All prophylactic drugs should be taken with unfailing regularity for the duration of stay in the malaria risk area, and continued for 4 weeks after the last possible exposure, since parasites may still emerge from the liver during this period."
- Park's PSM
So yes - 1 year in endemic area = 1 year of drug + 4 weeks after leaving. The "4 weeks after" rule applies regardless of how long the stay was - it covers the pre-erythrocytic (liver) stage incubation period.
Does not it cause any kind of adverse effect or toxicity
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Absolutely - long-term use does cause real adverse effects. Here's the complete toxicity profile for each prophylactic drug:
Adverse Effects of Malaria Chemoprophylaxis Drugs
1. Chloroquine (long-term weekly use)
Common (at prophylactic doses - generally mild)
- Headache, nausea, vomiting
- Blurred vision, dizziness, fatigue
- Pruritus - especially in people of African ancestry (responds to antihistamines)
Serious (with prolonged/high-dose use)
| Effect | Details |
|---|---|
| Retinopathy | The most feared long-term effect. Occurs with cumulative high doses used in rheumatology, but at prophylactic doses (300 mg/week), retinal damage has NOT been documented as a significant problem - this is the key distinction |
| Corneal deposits/keratopathy | Reversible deposits; blurred vision with halos |
| Cardiotoxicity | Arrhythmias, conduction defects (with overdose or IV use) |
| Neuropsychiatric | Rare seizures, psychosis |
| Blood dyscrasias | Rare |
| Exacerbates psoriasis | Important contraindication |
| Porphyria | Can precipitate attacks |
Key point: Chloroquine at prophylactic doses is considered safe even for years, BUT if taken for >3-5 years, 6-monthly ophthalmological screening is recommended. The retinal damage is mainly a concern at the higher doses used for rheumatoid arthritis/lupus.
2. Mefloquine (weekly - most problematic drug)
Common
- Nausea, dizziness, vivid/disturbing dreams
- Fatigue, lassitude
- Headache
Serious - FDA Black Box Warning
| Effect | Details |
|---|---|
| Neuropsychiatric effects | Anxiety, depression, acute psychosis, seizures - even at prophylactic doses |
| Cardiac | Depresses AV conduction → contraindicated with beta-blockers |
| Vestibular | Vertigo, tinnitus (especially with long-term use) |
Contraindicated in: history of epilepsy, psychiatric illness, cardiac conduction abnormalities, and in cerebral malaria patients
The neuropsychiatric effects can persist for months after stopping the drug - this is why it carries an FDA black box warning. The WHO recommends informing patients about these risks before starting.
3. Doxycycline (daily - most commonly used for long trips)
Common
- GI upset - nausea, vomiting, oesophageal ulceration (take with full glass of water, sit upright after)
- Photosensitivity - sunburn easily; must use high-SPF sunscreen daily
- Candidal vaginitis/oral thrush - due to disruption of normal flora with prolonged use
- Dental discolouration and bone growth inhibition in children <8 years
Serious
| Effect | Details |
|---|---|
| Oesophageal ulceration | If taken without water or lying down |
| Antibiotic-associated diarrhoea / C. difficile | With prolonged courses |
| Teratogenicity | Contraindicated in pregnancy |
Over 1 year: candidal infections and photosensitivity are the most practically troublesome issues
4. Atovaquone-Proguanil / Malarone (daily)
Generally the best-tolerated prophylactic drug
- Nausea, abdominal pain, headache, dizziness (usually mild)
- Mouth ulcers (from proguanil component)
- Rare: elevated liver enzymes
Serious
| Effect | Details |
|---|---|
| Renal | Contraindicated if CrCl <30 mL/min |
| Not in pregnancy | Safety not established |
Advantage: short post-travel duration (7 days) and good tolerability, but only formally studied up to 20 weeks - so for a 1-year stay, there is less long-term data.
5. Primaquine
- Abdominal cramps, epigastric distress, nausea
- Haemolytic anaemia - the major risk in G6PD-deficient patients (can be life-threatening) - MUST test G6PD before use
- Rare: neutropenia, methaemoglobinaemia, hypertension, arrhythmias
- Contraindicated in pregnancy and breastfeeding
6. Tafenoquine
- Generally better absorbed than primaquine, fewer GI effects
- Severe psychiatric reactions - contraindicated in psychiatric history
- Haemolysis in G6PD deficiency - same risk as primaquine
- Contraindicated in pregnancy and breastfeeding
Summary - Most Feared Adverse Effect per Drug
| Drug | Most Feared Long-Term Effect |
|---|---|
| Chloroquine | Retinopathy (at doses used for rheumatology; rare at prophylactic dose) |
| Mefloquine | Neuropsychiatric effects (psychosis, depression) - FDA Black Box |
| Doxycycline | Photosensitivity + candidal infections (long-term) |
| Atovaquone-Proguanil | Renal toxicity (if CrCl <30) |
| Primaquine / Tafenoquine | Haemolytic anaemia (G6PD deficiency) |
Bottom Line for Your Scenario (1-year stay)
Yes, taking any of these drugs for a full year is not without risk, which is why:
- Drug choice must match the individual - their medical history, contraindications, tolerability
- Regular monitoring is needed for long stays (ophthalmology for chloroquine, psychiatric review for mefloquine)
- The risks of prophylaxis must always be weighed against the risk of getting malaria - which in a hyperendemic area over 1 year is very high and potentially fatal
- Goldman-Cecil Medicine, Goodman & Gilman's Pharmacological Basis of Therapeutics, Park's PSM
This is a shared conversation. Sign in to Orris to start your own chat.